Your session is about to expire
← Back to Search
vancomycin for Clostridium Difficile Infection (StoP CDI Trial)
StoP CDI Trial Summary
This trial will test whether giving vancomycin to patients who are already colonized with C. diff will prevent them from getting CDI when they are admitted to the hospital for another infection.
- Clostridium Difficile (C. diff) Infection
StoP CDI Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.StoP CDI Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many persons are enrolled in this clinical experiment?
"Affirmative. Clinicaltrials.gov indicates that, since its initial posting on December 1st 2016 and most recent update on February 15th 2022, this clinical trial is actively searching for 2500 volunteers across a single location."
What prior research has been undertaken with regards to the use of vancomycin?
"Currently, 55 different studies are being conducted to investigate vancomycin. Within those experiments, 6 of them have progressed to the third phase of clinical trials. Of these 315 locations where research is taking place, a great deal are located in Jupiter, Florida."
Has the Food and Drug Administration granted its approval to vancomycin?
"There is a wealth of evidence in support of vancomycin's safety, thus it was given the maximum score of 3."
Are any additional participants being accepted for this experiment?
"The most current information on clinicaltrials.gov verifies that the trial is actively enrolling participants and has been since it was initially posted in December 2016 and later updated February 2022."
To what ailments is vancomycin commonly prescribed?
"Vancomycin is an effective therapeutic measure for treating afflictions like staphylococcal infections, infection caused by staphylococci, and enterocolitis brought on by Staphylococcus aureus."
Share this study with friends
Copy Link
Messenger